| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 30 Jan 2026 | 43 | 46% | 40% | 14% | 28% |
| 01 Jan 2025 - 30 Jun 2025 | 07 Apr 2026 | 54 | 35% | 38% | 27% | 53% |
| 01 Jan 2025 - 30 Jun 2025 | 26 Jul 2025 | 54 | 35% | 38% | 27% | 5% |
| 01 Jul 2024 - 31 Dec 2024 | 31 Jan 2025 | 49 | 38% | 34% | 28% | 7% |
| 01 Jan 2024 - 30 Jun 2024 | 07 Jul 2025 | 52 | 44% | 41% | 15% | 8% |
| 01 Jul 2023 - 31 Dec 2023 | 29 Jan 2024 | 46 | 47% | 43% | 10% | 7% |
| 01 Jan 2023 - 30 Jun 2023 | 27 Jul 2023 | 55 | 41% | 45% | 14% | 11% |
| 01 Jul 2022 - 31 Dec 2022 | 20 Jan 2023 | 52 | 42% | 45% | 14% | 8% |
| 01 Jan 2022 - 30 Jun 2022 | 25 Jul 2022 | 61 | 34% | 48% | 17% | 7% |
| 01 Jul 2021 - 31 Dec 2021 | 26 Jan 2022 | 58 | 35% | 50% | 15% | 8% |
| 01 Jan 2021 - 30 Jun 2021 | 19 Jul 2021 | 55 | 37% | 51% | 12% | 11% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 46 | 43% | 47% | 10% | 10% |
| 01 Jan 2020 - 30 Jun 2020 | 28 Jul 2020 | 48 | 46% | 42% | 12% | 11% |
| 01 Jul 2019 - 31 Dec 2019 | 29 Jan 2020 | 38 | 59% | 34% | 7% | 10% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 35 | 58% | 34% | 8% | 10% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 37 | 60% | 31% | 9% | 10% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 38 | 58% | 29% | 13% | 15% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Standard terms range from 0 to 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
Standard and maximum contractual payment terms exclude intercompany payment terms.
Maximum contractual payment period agreed
60
Any discrepancies between invoice and delivery/receipt of goods or services are fully investigated internally and the findings discussed in full with the supplier, with a view of resolving the difference and/or negotiating settlement. Invoices are classified as disputed only where a dispute is formally recorded in accounts payable systems. Disputes are usually resolved through negotiations with suppliers and the issuance of revised invoices or credit notes and are not identifiable through our systems for reporting purposes.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Amgen Limited is the UK-registered entity of Amgen, a biotechnology group headquartered in the United States. Its registered SIC code covers research and experimental development in biotechnology, and it is based at Cambridge Science Park. The wider Amgen group discovers, develops and manufactures biologic medicines for serious illnesses, including cardiovascular disease, obesity, rare diseases, inflammatory conditions and cancer, using living cells and human genetic data in its research. Amgen Limited operates as part of this global group's presence in the UK, contributing to research activity, rather than independently manufacturing or marketing medicines under its own name. The company remains active and has been incorporated since 1989.
Generated from the company's website and Companies House records. Sources: amgen.com · amgen.com